Kyntra Bio, Inc.
KYNB
$6.82
-$0.19-2.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 18.68% | -20.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 18.68% | -20.18% | |||
| Cost of Revenue | 555.60% | -80.66% | |||
| Gross Profit | -8,258.67% | 98.37% | |||
| SG&A Expenses | 36.92% | -24.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 129.54% | -50.44% | |||
| Operating Income | -151.75% | 53.94% | |||
| Income Before Tax | -11.14% | 4.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.14% | 3.92% | |||
| Earnings from Discontinued Operations | -99.82% | 3,416.15% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -107.09% | 2,738.91% | |||
| EBIT | -151.75% | 53.94% | |||
| EBITDA | -160.93% | 54.73% | |||
| EPS Basic | -107.08% | 2,737.60% | |||
| Normalized Basic EPS | -124.00% | 51.29% | |||
| EPS Diluted | -107.08% | 2,737.60% | |||
| Normalized Diluted EPS | -124.00% | 51.29% | |||
| Average Basic Shares Outstanding | 0.05% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||